A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Posted byadmin 27. July 2020 Dittrich, C, Fridrik, MA, Koenigsberg, R, Lee, C, Goeldner, R, Hilbert, J, Greil, R. http://www.ncbi.nlm.nih.gov/pubmed/25529193